Manufacturer of Controlled Substances; Notice of Registration, 72840 [E8-28432]
Download as PDF
<![CDATA[
72840
Federal Register / Vol. 73, No. 231 / Monday, December 1, 2008 / Notices
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Global Universal Design Commission,
Inc. (‘‘GUDC’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing (1) the name and
principal place of business of the
standards development organization
and (2) the nature and scope of its
standards development activities. The
notifications were filed for the purpose
of invoking the Act’s provisions limiting
the recovery of antitrust plaintiffs to
actual damages under specified
circumstances.
Pursuant to Section 6(b) of the Act,
the name and principal place of
business of the standards development
organization is: Global Universal Design
Commission, Inc., Syracuse, New York.
The nature and scope of GUDC’s
standards development activities are: To
develop and promote the understanding
and use of universal design. Universal
design seeks to increase the usability,
safety and health of the built
environment to support social inclusion
of a diverse population in all aspects of
society. Universal design is an approach
to the design of products and
environment which treats all people
equally and does not call special
attention to the needs of a particular
class of people. GUDC seeks to develop
universal design standards through a
consensus process that will increase
choices and accommodate a wide range
of preferences and needs, to the greatest
extent possible, without the need for
adaptation, retrofitting, or specialized
design.
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. E8–28193 Filed 11–28–08; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
rwilkins on PROD1PC63 with NOTICES
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated July 29, 2008, and
published in the Federal Register on
August 6, 2008 (73 FR 45784),
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
VerDate Aug<31>2005
16:47 Nov 28, 2008
Jkt 217001
substance in the preparation of
analytical standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cambridge Isotope Lab to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Cambridge Isotope Lab to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: November 21, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–28432 Filed 11–28–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OMB Number 1121–NEW]
Agency Information Collection
Activities: Proposed Collection;
Comments Requested
60-day Notice of new collection:
Methodological research to support the
redesign of the National Crime
Victimization Survey (NCVS).
ACTION:
The Department of Justice (DOJ),
Office of Justice Programs, Bureau of
Justice Statistics will be submitting the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection is published to
obtain comments from the public and
affected agencies. Comments are
encouraged and will be accepted for
‘‘sixty days’’ until January 30, 2009.
This process is conducted in accordance
with 5 CFR 1320.10.
If you have comments especially on
the estimated public burden or
associated response time, suggestions,
or need a copy of the proposed
information collection instrument with
instructions or additional information,
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
please contact Katrina Baum,
Statistician, Bureau of Justice Statistics,
Office of Justice Programs, Department
of Justice, 810 7th Street, NW.,
Washington, DC 20531, or facsimile
(202) 307–1463.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address one or more
of the following four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agencies
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Enhance the quality, utility, and
clarity of the information to be
collected; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
Overview of This information
(1) Type of information collection:
New collection.
(2) Title of the Form/Collection:
Methodological research to support the
redesign of the National Crime
Victimization Survey (NCVS).
(3) Agency form number, if any, and
the applicable component of the
department sponsoring the collection:
Form numbers not available for generic
clearance, Bureau of Justice Statistics,
Office of Justice Programs, Department
of Justice.
(4) Affected public who will be asked
or required to respond, as well as a brief
abstract. Primary: Persons ages 12 or
older in sampled households in the
United States.
(5) An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond/reply: Approximately 43,180
persons ages 12 or older will be
interviewed for some aspect of the
redesign research. The average length of
interview will vary by the type of
interview conducted. Completing the
crime screener and abbreviated incident
report is estimated to take 15 minutes,
while a cognitive interview for
improving recall using event history
calendars may take 2 hours.
E:\FR\FM\01DEN1.SGM
01DEN1
]]>Agencies
[Federal Register Volume 73, Number 231 (Monday, December 1, 2008)]
[Notices]
[Page 72840]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-28432]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated July 29, 2008, and published in the Federal
Register on August 6, 2008 (73 FR 45784), Cambridge Isotope Lab, 50
Frontage Road, Andover, Massachusetts 01810, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of Morphine (9300), a basic class of controlled
substance listed in schedule II.
The company plans to utilize small quantities of the listed
controlled substance in the preparation of analytical standards.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Cambridge Isotope Lab to manufacture the listed basic class of
controlled substance is consistent with the public interest at this
time. DEA has investigated Cambridge Isotope Lab to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic class of controlled substance listed.
Dated: November 21, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-28432 Filed 11-28-08; 8:45 am]
BILLING CODE 4410-09-P
